Beacon Transcript

Information which Matters to You

Tuesday, January 26, 2021
Log in
  • National News
  • National News
  • Business
  • Business
  • Technology
  • Technology
  • Health
  • Health
  • Science
  • Science
  • About Us
    • Contact Us
    • Authors & Contributors
    • Privacy Policy GDPR
  • About Us
    • Contact Us
    • Authors & Contributors
    • Privacy Policy GDPR

Recent Articles

Ancient Babylonian Clay Tablet Holds the First Trigonometric Table

Ancient Babylonian Clay Tablet Holds the First Trigonometric Table

August 26, 2017 By Clayton Meason

The CDC Draws Attention To The Spike In Cyclosporiasis Cases

The CDC Draws Attention To The Spike In Cyclosporiasis Cases

August 11, 2017 By Troy G. Bennett

Travis Kalanick Resigns from His Position as Uber’s CEO

Travis Kalanick Resigns from His Position as Uber’s CEO

June 22, 2017 By Troy G. Bennett

Amazon Refunds Parents Whose Children Made Purchases Without Permission

Amazon Refunds Parents Whose Children Made Purchases Without Permission

June 2, 2017 By Clayton Meason

McDonald’s Has Been Quietly Altering Its Vanilla Ice Cream Recipe

McDonald’s Has Been Quietly Altering Its Vanilla Ice Cream Recipe

May 21, 2017 By Jennifer Licata

Washington Post Will Be Expanding Its Newsroom

Washington Post Will Be Expanding Its Newsroom

December 28, 2016 By Troy G. Bennett

SciClone Pharmaceuticals Climbs To Near 15-Year High

March 12, 2015 By Gary Wymore

Email, RSS Follow

SciClone Pharmaceuticals shares rose to their highest level since 2000 in mid-morning trade Thursday after the specialty pharmaceutical company reported better-than-expected Q4 results late Wednesday. Shares were most recently higher 17%, down from the earlier high of $9.65. The 52-week low is at $4.24.

The company said Q4 sales were $41.4 million, more than the Cap IQ estimate for $38.93 million. Non-GAAP EPS rose to $0.29 from $0.07 a year ago and beat estimates for $0.16.

Reported earnings rose to $3.5 million or $0.07 per diluted share from $36,000 or $0.00 per share a year earlier.

It sees FY15 sales between $153 million and $158 million, driven by ZADAXIN revenues, and non-GAAP EPS between $0.73 and $0.77. Analysts are looking for revenue of $155 million and EPS of $0.61.

Email, RSS Follow

Filed Under: Stocks

Recent Posts

  • Security Guard List As Suspect in 1974 Stanford University Chapel Slaying Kills Himself June 29, 2018
  • Texas Teens Arrested After Decomposing Body of Elderly Woman Found in Garage June 28, 2018
  • Montana Woman in Custody After Forcing Ex to Have Sex with Her June 27, 2018
  • Newly Released Audio Transcript Proves Monalisa Perez Objected to Deadly YouTube Prank June 26, 2018
  • Virginia Woman Shoots New Zealand Man Who Smashed Glass Door with Brick   June 26, 2018
  • Arizona Woman Lied About Kidnapping to Cover Boyfriend’s Slaying June 25, 2018
  • Brooklyn Man Arrested in Niagara Falls Allegedly Chopped off Pregnant Wife’s Arms with Steak Knife June 25, 2018

Related Articles

  • Rosetta Stone Tumbles 11% on Q4 Sales Miss

    Mar 12, 2015
  • United Technologies to Explore Strategic Options

    Mar 12, 2015
  • Targa Resources Slips

    Mar 12, 2015
  • Cannabis Kinetics Corp. to Launch Re-Branded Monarch America Social Media Strategy

    Dec 10, 2014

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Science
  • Stocks
  • Technology
  • US
  • World

Copyright © 2021 beacontranscript.com

About · Privacy Policy · Terms of Use · Contact

This website uses cookies to ensure you get the best experience on our website. Learn more.